Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner ...

In response, teaching staff should identify where gaps lie and invest time in creating constructive sessions to overcome this. We have found the following initiatives helpful in supporting a smoother ...

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients ...

BEND, Ore. (KTVZ) -- A Bend company focused on developing new drugs is expanding and has just opened a new state-of-the-art facility to support clinical trials. "We focus on the early stages of the ...

The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell ...

Margaret R. McLean delivered this address to the Keck Graduate Institute Convocation in September 2010. She is associate director of the Markkula Center for Applied Ethics and Director of Bioethics.

Zivo Bioscience ( ($ZIVO) ) has provided an update. On December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned ...

Vyne Therapeutics is set to combine with Yarrow Bioscience in an all-stock merger. Vyne, a clinical-stage biopharmaceutical company, and Yarrow Bioscience, a clinical-stage biotechnology company said ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Until recently, most commercial cannabis growers relied on clones, but a seed-based production revolution is on the horizon. Phylos Bioscience seeds provide exceptional uniformity with desired ...